These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 21235130)
21. Copper-67 as a therapeutic nuclide for radioimmunotherapy. Novak-Hofer I; Schubiger PA Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):821-30. PubMed ID: 12029558 [TBL] [Abstract][Full Text] [Related]
22. Advancing role of radiolabeled antibodies in the therapy of cancer. Goldenberg DM Cancer Immunol Immunother; 2003 May; 52(5):281-96. PubMed ID: 12700944 [TBL] [Abstract][Full Text] [Related]
23. Effectiveness of radiolabelled antibodies for radio-immunotherapy in a colorectal xenograft model: a comparative study using the linear--quadratic formulation. Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Dearling J; Bhatia J; Begent RH Int J Radiat Biol; 2001 Apr; 77(4):507-17. PubMed ID: 11304442 [TBL] [Abstract][Full Text] [Related]
25. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator. Su FM; Beaumier P; Axworthy D; Atcher R; Fritzberg A Nucl Med Biol; 2005 Oct; 32(7):741-7. PubMed ID: 16243650 [TBL] [Abstract][Full Text] [Related]
26. Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I/II trial. Vuillez JP; Kraeber-Bodéré F; Moro D; Bardiès M; Douillard JY; Gautherot E; Rouvier E; Barbet J; Garban F; Moreau P; Chatal JF Clin Cancer Res; 1999 Oct; 5(10 Suppl):3259s-3267s. PubMed ID: 10541373 [TBL] [Abstract][Full Text] [Related]
27. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model. Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357 [TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma. Maraveyas A; Stafford N; Rowlinson-Busza G; Stewart JS; Epenetos AA Cancer Res; 1995 Mar; 55(5):1060-9. PubMed ID: 7866989 [TBL] [Abstract][Full Text] [Related]
29. Comparison between radioimmunotherapy and external beam radiation therapy for patients with hepatocellular carcinoma. Zeng ZC; Tang ZY; Yang BH; Liu KD; Wu ZQ; Fan J; Qin LX; Sun HC; Zhou J; Jiang GL Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1657-68. PubMed ID: 12458401 [TBL] [Abstract][Full Text] [Related]
30. Radioimmunotherapy of CD22-expressing Daudi tumors in nude mice with a 90Y-labeled anti-CD22 monoclonal antibody. Vallera DA; Brechbiel MW; Burns LJ; Panoskaltsis-Mortari A; Dusenbery KE; Clohisy DR; Vitetta ES Clin Cancer Res; 2005 Nov; 11(21):7920-8. PubMed ID: 16278417 [TBL] [Abstract][Full Text] [Related]
31. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters. Behr TM; Sgouros G; Stabin MG; Béhé M; Angerstein C; Blumenthal RD; Apostolidis C; Molinet R; Sharkey RM; Koch L; Goldenberg DM; Becker W Clin Cancer Res; 1999 Oct; 5(10 Suppl):3031s-3043s. PubMed ID: 10541340 [TBL] [Abstract][Full Text] [Related]
32. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies. Behr TM; Sharkey RM; Juweid ME; Dunn RM; Ying Z; Zhang CH; Siegel JA; Goldenberg DM J Nucl Med; 1997 Mar; 38(3):409-18. PubMed ID: 9074529 [TBL] [Abstract][Full Text] [Related]
33. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma. Divgi CR; Scott AM; Dantis L; Capitelli P; Siler K; Hilton S; Finn RD; Kemeny N; Kelsen D; Kostakoglu L J Nucl Med; 1995 Apr; 36(4):586-92. PubMed ID: 7699446 [TBL] [Abstract][Full Text] [Related]
34. Threshold estimation in single photon emission computed tomography and planar imaging for clinical radioimmunotherapy. Erdi YE; Wessels BW; Loew MH; Erdi AK Cancer Res; 1995 Dec; 55(23 Suppl):5823s-5826s. PubMed ID: 7493353 [TBL] [Abstract][Full Text] [Related]
36. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo. Bäck T; Andersson H; Divgi CR; Hultborn R; Jensen H; Lindegren S; Palm S; Jacobsson L J Nucl Med; 2005 Dec; 46(12):2061-7. PubMed ID: 16330571 [TBL] [Abstract][Full Text] [Related]
37. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105 [TBL] [Abstract][Full Text] [Related]
38. Antibody and radionuclide characteristics and the enhancement of the effectiveness of radioimmunotherapy by selective dose delivery to radiosensitive areas of tumour. Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Bhatia J; Morris R; Begent RH Int J Radiat Biol; 2002 May; 78(5):407-15. PubMed ID: 12020430 [TBL] [Abstract][Full Text] [Related]
39. Simulation Study on Effects of Order and Step Size of Runge-Kutta Methods that Solve Contagious Disease and Tumor Models. Wang Z; Wang Q; Klinke DJ J Comput Sci Syst Biol; 2016 Sep; 9(5):163-172. PubMed ID: 28220053 [TBL] [Abstract][Full Text] [Related]
40. Time for radioimmunotherapy: an overview to bring improvements in clinical practice. Leaman Alcibar O; Candini D; López-Campos F; Albert Antequera M; Morillo Macías V; Conde AJ; Rodríguez Pérez A; Hervás Morón A; Contreras Martínez J; Ferrer Albiach C; Navarro Aguilar S; Rodríguez-Ruiz ME Clin Transl Oncol; 2019 Aug; 21(8):992-1004. PubMed ID: 30644044 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]